A detailed history of Northern Trust Corp transactions in Rezolute, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 96,957 shares of RZLT stock, worth $426,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,957
Previous 67,182 44.32%
Holding current value
$426,610
Previous $288,000 63.19%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.13 - $5.31 $122,970 - $158,105
29,775 Added 44.32%
96,957 $470,000
Q2 2024

Aug 14, 2024

SELL
$2.29 - $5.79 $100 - $254
-44 Reduced 0.07%
67,182 $288,000
Q1 2024

May 14, 2024

SELL
$0.95 - $2.55 $15,922 - $42,738
-16,760 Reduced 19.96%
67,226 $171,000
Q4 2023

Feb 13, 2024

SELL
$0.74 - $1.24 $1,423 - $2,384
-1,923 Reduced 2.24%
83,986 $83,000
Q3 2023

Nov 13, 2023

SELL
$1.32 - $2.1 $143 - $228
-109 Reduced 0.13%
85,909 $113,000
Q2 2023

Aug 11, 2023

BUY
$1.75 - $2.33 $19,633 - $26,140
11,219 Added 15.0%
86,018 $170,000
Q1 2023

May 15, 2023

SELL
$1.79 - $2.87 $20,132 - $32,278
-11,247 Reduced 13.07%
74,799 $143,000
Q4 2022

Feb 13, 2023

SELL
$1.38 - $2.84 $510 - $1,050
-370 Reduced 0.43%
86,046 $178,000
Q3 2022

Nov 14, 2022

BUY
$2.19 - $3.49 $2,888 - $4,603
1,319 Added 1.55%
86,416 $236,000
Q2 2022

Aug 12, 2022

BUY
$2.6 - $3.85 $87,310 - $129,286
33,581 Added 65.19%
85,097 $274,000
Q1 2022

May 13, 2022

SELL
$2.27 - $5.1 $1,763 - $3,962
-777 Reduced 1.49%
51,516 $174,000
Q4 2021

Feb 08, 2022

BUY
$4.21 - $7.61 $69,018 - $124,758
16,394 Added 45.67%
52,293 $250,000
Q3 2021

Nov 15, 2021

BUY
$7.45 - $13.66 $28,123 - $51,566
3,775 Added 11.75%
35,899 $269,000
Q2 2021

Aug 13, 2021

BUY
$6.11 - $15.99 $196,277 - $513,662
32,124 New
32,124 $459,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $171M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.